tetano
Editor, Senior Moderator
Int J Infect Dis
. 2022 Apr 29;S1201-9712(22)00258-2.
doi: 10.1016/j.ijid.2022.04.058. Online ahead of print.
A Fatal Breakthrough Coronavirus Disease 2019 Case Following Bendamustine-Rituximab Therapy
Kohei Kamegai[SUP] 1 [/SUP], Noriko Iwamoto[SUP] 1 [/SUP], Tomiteru Togano[SUP] 1 [/SUP], Kenji Maeda[SUP] 1 [/SUP], Yuki Takamatsu[SUP] 1 [/SUP], Yusuke Miyazato[SUP] 1 [/SUP], Masahiro Ishikane[SUP] 1 [/SUP], Masashi Mizokami[SUP] 1 [/SUP], Masaya Sugiyama[SUP] 1 [/SUP], Shun Iida[SUP] 2 [/SUP], Sho Miyamoto[SUP] 2 [/SUP], Tadaki Suzuki[SUP] 2 [/SUP], Norio Ohmagari[SUP] 3 [/SUP]
Affiliations
Abstract
Although messenger ribonucleic acid vaccines are substantially effective toward severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, patients with hematological malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serological study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.
Keywords: COVID-19; bendamustine–rituximab therapy; breakthrough; fatal; immune escape.
. 2022 Apr 29;S1201-9712(22)00258-2.
doi: 10.1016/j.ijid.2022.04.058. Online ahead of print.
A Fatal Breakthrough Coronavirus Disease 2019 Case Following Bendamustine-Rituximab Therapy
Kohei Kamegai[SUP] 1 [/SUP], Noriko Iwamoto[SUP] 1 [/SUP], Tomiteru Togano[SUP] 1 [/SUP], Kenji Maeda[SUP] 1 [/SUP], Yuki Takamatsu[SUP] 1 [/SUP], Yusuke Miyazato[SUP] 1 [/SUP], Masahiro Ishikane[SUP] 1 [/SUP], Masashi Mizokami[SUP] 1 [/SUP], Masaya Sugiyama[SUP] 1 [/SUP], Shun Iida[SUP] 2 [/SUP], Sho Miyamoto[SUP] 2 [/SUP], Tadaki Suzuki[SUP] 2 [/SUP], Norio Ohmagari[SUP] 3 [/SUP]
Affiliations
- PMID: 35500795
- DOI: 10.1016/j.ijid.2022.04.058
Abstract
Although messenger ribonucleic acid vaccines are substantially effective toward severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, patients with hematological malignancies are still prone to the virus. Herein, we report a fatal case of breakthrough SARS-CoV-2 delta variant infection in a patient with mucosa-associated lymphoid tissue lymphoma with remission by bendamustine-rituximab (BR) therapy completed a year ago. The serological study revealed impaired responsiveness toward vaccines and prolonged high viral load after infection. BR therapy seemingly induced an immune escape. Prevention and treatment strategies for such vulnerable patients should be clarified immediately.
Keywords: COVID-19; bendamustine–rituximab therapy; breakthrough; fatal; immune escape.